Work

Linezolid for Treating Tuberculosis: A Delicate Balancing Act

Year: 2015

Type: article

Abstract: There is an urgent need for better regimens to treat drug-resistant tuberculosis (DR-TB). Treatment for multi-drug resistant tuberculosis (MDR-TB, defined as resistance to both isoniazid and rifampicin) has a success rate of only 64% (Falzon et al., 2013), is prolonged for up to 24months, and is poorly tolerated. Treatment success for extensively drug-resistant tuberculosis (XDR-TB, defined as MDR-TB with additional resistance to fluoroquinolones and an injectable) is only 40% (Falzon et al., 2013).

Source: EBioMedicine

DOI: 10.1016/j.ebiom.2015.10.014

Authors: Gary Maartens, Constance A. Benson

Institutions: University of Cape Town, University of California San Diego

Language: English

Topic: Tuberculosis Research and Epidemiology

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $5,780